electroCore, Inc.
ECORelectroCore, Inc. in brief
electroCore, Inc. is a listed company in the Medical Instruments industry, based in Rockaway, New Jersey, USA. Its market value was $75 M on 30 October 2026, which makes it the 19,820th largest listed company in the world and the 3,678th largest in the USA on this site. In the year to December 2025 it had sales of $32 M and a net loss of $14 M. It employs about 83 people and Daniel Goldberger is its chief executive. Its largest product and service lines by sales in 2025 were License (under 1%). Its shares trade under the symbol ECOR (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
electroCore, Inc. timeline
- 2012
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2018
- ✎Renamed electroCore, Inc.Formerly ElectroCore, LLC.
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 25 June 2018; shares registered for exchange trading on 18 June 2018.
- 2025
- 💰Record revenue of $32 millionFY2025, the highest of the 8 years on record.
Events of electroCore, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,174 (Jan 2020) · #3,880 (Jan 2021) · #5,036 (Jan 2022) · #5,242 (Dec 2022) · #5,165 (Jul 2023) · #4,179 (Jan 2024) · #2,119 (Mar 2026) · #3,482 (Aug 2026) · #3,583 (Oct 2026) · #3,682 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 2.0×
- Price / book
- —
- Free cash flow yield
- -11.0%
- Net margin (TTM)
- -33.5%
- Operating margin
- -41.1%
- Return on equity
- —
- Liabilities / assets
- 109.2%
- Net debt
- $1M
- Revenue growth
- +27.2%
- R&D / revenue
- 9.4%
- Revenue per employee
- $386 K
- Profit per employee
- $-168 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $32M | +27.2% | $-13M | $-14M | -43.6% |
| Dec 2024 | $25M | +57.1% | $-12M | $-12M | -47.2% |
| Dec 2023 | $16M | +86.6% | $-19M | $-19M | -117.5% |
| Dec 2022 | $9M | +57.6% | $-23M | $-22M | -258.0% |
| Dec 2021 | $5M | +55.7% | $-20M | $-17M | -316.0% |
| Dec 2020 | $4M | +46.4% | $-25M | $-24M | -671.7% |
| Dec 2019 | $2M | +141.4% | $-46M | $-45M | -1889.1% |
| Dec 2018 | $1M | — | $-55M | $-56M | -5638.4% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-8M | $0M | $-8M | $-1.65 | — |
| Dec 2024 | $-7M | — | — | $-1.59 | — |
| Dec 2023 | $-15M | $0M | $-15M | $-3.42 | — |
| Dec 2022 | $-17M | — | — | $-4.69 | — |
| Dec 2021 | $-14M | — | — | $-4.36 | — |
| Dec 2020 | $-20M | — | — | $-0.60 | — |
| Dec 2019 | $-45M | $0M | $-45M | $-1.54 | — |
| Dec 2018 | $-47M | $0M | $-47M | $-1.19 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $10M (+11.5% on a year earlier), net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 4, 202610-QQuarterly report · period to Sep 2026
- Nov 4, 20268-KCurrent reportResults of operations
- Sep 9, 20268-KCurrent reportDirectors or officers changed · Bylaws amended · Shareholder vote · Regulation FD disclosure
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportResults of operations
- Jul 20, 2026DEF 14AProxy statement
- May 6, 202610-QQuarterly report · period to Mar 2026
- May 6, 20268-KCurrent reportResults of operations
- Mar 19, 202610-KAnnual report · period to Dec 2025
- Mar 19, 20268-KCurrent reportResults of operations
- Jan 20, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Nov 5, 202510-QQuarterly report · period to Sep 2025
Official filings of electroCore, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $32 M
- Operating income
- $-13 M
- Net income
- $-14 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $19 M
- Total liabilities
- $20 M
- Total equity
- $-2 M
As of December-2025
Top 40 institutional investors in electroCore, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Wexford Capital LP | 293,901 | +201,841 (+219.25%) | 3.19% | $3 M | Nov 13, 2026 |
| 2 | Vanguard Capital Management LLC | 211,639 | 0 (0.00%) | 2.29% | $2 M | Nov 13, 2026 |
| 3 | FourWorld Capital Management LLC | 165,649 | +71,649 (+76.22%) | 1.80% | $2 M | Nov 16, 2026 |
| 4 | Citadel Advisors LLC | 158,708 | +114,905 (+262.32%) | 1.72% | $2 M | Nov 16, 2026 |
| 5 | Geode Capital Management, LLC | 68,176 | -4,973 (-6.80%) | 0.74% | $1 M | Nov 6, 2026 |
| 6 | Jaffetilchin Investment Partners, LLC | 59,954 | 0 (0.00%) | 0.65% | $1 M | Nov 16, 2026 |
| 7 | Quadrature Capital Ltd | 54,832 | New | 0.59% | $1 M | Nov 13, 2026 |
| 8 | Wealthspire Advisors, LLC | 46,679 | -819 (-1.72%) | 0.51% | $1 M | Nov 13, 2026 |
| 9 | Vanguard Fiduciary Trust Co | 38,770 | 0 (0.00%) | 0.42% | $0 M | Nov 13, 2026 |
| 10 | HighTower Advisors, LLC | 35,342 | 0 (0.00%) | 0.38% | $0 M | Nov 10, 2026 |
| 11 | BlackRock, Inc. | 34,001 | +2,225 (+7.00%) | 0.37% | $0 M | Nov 13, 2026 |
| 12 | Cetera Investment Advisers | 32,950 | New | 0.36% | $0 M | Nov 13, 2026 |
| 13 | Evercore Wealth Management, LLC | 31,957 | New | 0.35% | $0 M | Nov 16, 2026 |
| 14 | Marshall Wace, LLP | 30,954 | -12,718 (-29.12%) | 0.34% | $0 M | Nov 13, 2026 |
| 15 | Wealth Enhancement Advisory Services, LLC | 25,978 | New | 0.28% | $0 M | Oct 13, 2026 |
| 16 | State Street Corp | 25,018 | -1,500 (-5.66%) | 0.27% | $0 M | Nov 12, 2026 |
| 17 | Bridgeway Capital Management, LLC | 25,000 | 0 (0.00%) | 0.27% | $0 M | Nov 16, 2026 |
| 18 | Jane Street Group, LLC | 23,406 | -39,996 (-63.08%) | 0.25% | $0 M | Nov 12, 2026 |
| 19 | XTX Topco Ltd | 19,336 | New | 0.21% | $0 M | Nov 16, 2026 |
| 20 | Renaissance Technologies LLC | 17,800 | -2,100 (-10.55%) | 0.19% | $0 M | Nov 12, 2026 |
| 21 | Northern Trust Corp | 15,067 | -51,439 (-77.34%) | 0.16% | $0 M | Nov 16, 2026 |
| 22 | HRT Financial LP | 15,034 | New | 0.16% | $0 M | Nov 13, 2026 |
| 23 | Tobias Financial Advisors, Inc. | 10,000 | 0 (0.00%) | 0.11% | $0 M | Nov 13, 2026 |
| 24 | UBS Group AG | 4,430 | -2,148 (-32.65%) | 0.05% | $0 M | Nov 10, 2026 |
| 25 | Morgan Stanley | 4,252 | +3,785 (+810.49%) | 0.05% | $0 M | Nov 13, 2026 |
Show all 40: investors 26 to 40
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Bfsg, LLC | 3,862 | 0 (0.00%) | 0.04% | $0 M | Oct 30, 2026 |
| 27 | Rockefeller Capital Management L.P. | 1,946 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 28 | Vanguard Global Advisers, LLC | 1,771 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 29 | Kozak & Associates, Inc. | 666 | 0 (0.00%) | 0.01% | $0 M | Oct 29, 2026 |
| 30 | Wells Fargo & Company/mn | 598 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 31 | Tower Research Capital LLC (TRC) | 326 | New | 0.00% | $0 M | Nov 16, 2026 |
| 32 | Prestige Wealth Management Group LLC | 270 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 33 | Royal Bank Of Canada | 169 | New | 0.00% | $0 M | Nov 16, 2026 |
| 34 | Allworth Financial LP | 72 | 0 (0.00%) | 0.00% | $0 M | Nov 17, 2026 |
| 35 | Northwestern Mutual Wealth Management Co | 28 | New | 0.00% | $0 M | Nov 13, 2026 |
| 36 | BNP Paribas Financial Markets | 24 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 37 | Provenance Wealth Advisors, LLC | 13 | New | 0.00% | $0 M | Oct 30, 2026 |
| 38 | Caitong International Asset Management Co., Ltd | 12 | New | 0.00% | $0 M | Oct 29, 2026 |
| 39 | IFP Advisors, Inc | 2 | New | 0.00% | $0 M | Oct 16, 2026 |
| 40 | Jpmorgan Chase & Co | 1 | -73 (-98.65%) | 0.00% | $0 M | Nov 12, 2026 |
Mutual funds holding electroCore, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 140,700 | $1 M | 1.5% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 61,702 | $1 M | 0.67% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 33,074 | $0 M | 0.36% | <0.01% | +8.1% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 17,562 | $0 M | 0.19% | <0.01% | +30% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 10,837 | $0 M | 0.12% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 8,975 | $0 M | 0.10% | <0.01% | +9.9% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 8,735 | $0 M | 0.09% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 2,537 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 1,200 | $0 M | 0.01% | <0.01% | +41% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 8,114 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 2,019 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 1,867 | $0 M | — | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 12 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at electroCore, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Thomas J. ErricoDirector | Buy | +10,000 | $5.440 | $54 K | 373,904 | Form 4 |
| filed | Thomas J. ErricoDirector | Buy | +5,000 | $9.820 | $49 K | 363,904 | Form 4 |
| filed | Michael FoxSee Remarks | Buyamended | +5,000 | $9.800 | $49 K | 130,000 | Form 4/A |
| filed | Michael FoxSee Remarks | Grant or award | +5,000 | $9.800 | $49 K | 130,000 | Form 4 |
| filed | Elena BonfiglioliDirector | Grant or award | +11,123 | — | — | 41,672 | Form 4 |
| filed | Patricia WilberDirector | Grant or award | +11,123 | — | — | 83,448 | Form 4 |
| filed | James Charles TheofilosDirector | Grant or award | +11,123 | — | — | 34,670 | Form 4 |
| filed | John P. GandolfoDirector | Grant or award | +11,123 | — | — | 99,221 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: electroCore, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 2,131 shares at $8.11
- : 1,642 shares at $7.76
- : 118 shares at $7.44
- : 809 shares at $7.41
- : 154 shares at $7.85
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
electroCore, Inc. scorecard#
Passes 8 of the 19 checks that could be worked out: strongest in growth (5 of 6), weakest in valuation (1 of 5). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✓Price to sales below its peers' median2.0×Price to sales 2.0× against Medical Instruments's median of 3.0×.
- ✗Free cash flow yield above 5%-11.0%Free cash flow is -11.0% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth5 of 6
- ✓Revenue grew in the newest year27.2%Revenue up 27.2% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years55.1%55.1% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median55.1%55.1% a year against Medical Instruments's median of 5.0% (37 companies).
- ✗Earnings per share grew in the newest year-1.65 vs -1.59Diluted EPS -1.65 in fiscal 2025 against -1.59 the year before (report's currency).
- ✓Net income higher than five years earlier-$14 M-$14 M in fiscal 2025 against -$24 M in 2020.
- ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
Profitability1 of 4
- ✗Profitable in the newest year-$14 MNet income -$14 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-41.1%-41.1% against Medical Instruments's median of 7.2% (46 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-41.1%-41.1% in fiscal 2025 against -266.2% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities1.4×Current ratio 1.38 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-12.46Z-score -12.46 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year14.3%Diluted shares up 14.3% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Medical Instruments, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from electroCore, Inc.'s statements, beside the median of Medical Instruments.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -41.1% | 7.2% | |
| Net margin | -43.6% | 3.8% | |
| Revenue growth, 3 years a year | 55.1% | 5.0% | |
| Revenue growth | 27.2% | 8.9% | |
| Free cash flow margin | -25.8% | 6.3% |
3of 8on the Piotroski tests of financial strength
- Net loss of $14 million, the 9th loss-making year in a row.
- Free cash flow was negative: -$8 million.
- The share count rose 14.3% in the year.
- Shareholders' equity is negative: -$2 million.
electroCore, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 32+27.2%100% | 25+57.1%100% | 16+86.6%100% | 8.6+57.6%100% | 5.5r5.5+55.9%100% | 3.5+46.3%100% | 2.4+141%100% | 1.0+22.4%100% | 0.8—100% | |
| Cost of revenue | 4.2+12.1%13.2% | 3.8+35.0%15.0% | 2.8+73.5%17.5% | 1.6+16.7%18.8% | 1.4r1.4−20.3%25.4% | 1.7+50.2%49.7% | 1.2+99.9%48.4% | 0.6+11.6%58.3% | 0.5—63.9% | |
| Gross profit | 28+29.9%86.8% | 21+61.8%85.0% | 13+89.6%82.5% | 7.0+71.6%81.2% | 4.1r4.1+131%74.6% | 1.8+42.6%50.3% | 1.2+198%51.6% | 0.4+41.4%41.7% | 0.3—36.1% | |
| Research and development | — | 2.4−55.6%9.4% | 5.3−3.6%33.2% | 5.5+118%64.2% | 2.5r2.5−39.6%46.5% | 4.2−57.6%120% | 9.9−20.6%414% | 12+59.2%1255% | 7.8—965% | |
| Selling, general and administrative | 38+22.5%119% | 31+14.8%124% | 27+11.7%170% | 24+12.8%283% | 22r22−1.2%396% | 22−38.3%625% | 35−16.7%1482% | 43+135%4280% | 18—2231% | |
| Operating expenses | 41+22.0%128% | 34+3.3%133% | 32+8.9%203% | 30+23.8%347% | 24r24−9.0%442% | 27−44.0%758% | 47−13.9%1980% | 55+112%5536% | 26—3196% | |
| Operating income | −13—−41.1% | −12—−48.3% | −19—−120% | −23—−266% | −20r−20—−368% | −25—−708% | −46—−1928% | −55—−5494% | −26—−3160% | |
| Interest expense and finance costs | 0.0−19.0%0.0% | 0.0—0.1% | — | 0.0—0.0% | — | 0.0−90.1%0.0% | 0.0—0.1% | — | 6.3—776% | |
| Other non-operating income (expense) | −0.8−543%−2.5% | 0.2−26.5%0.7% | 0.2−11.4%1.6% | 0.3−85.8%3.3% | 2.0r2.0+2865%36.2% | 0.1−93.1%1.9% | 1.0—40.1% | −1.2—−122% | −10—−1280% | |
| Income before tax | −14—−43.6% | −12—−47.6% | −19—−119% | −23—−263% | −18r−18—−331% | −25—−706% | −45—−1888% | −56—−5616% | −36—−4440% | |
| Income tax | 0.0—0.0% | −0.1—−0.4% | −0.2—−1.2% | −0.4—−5.0% | −0.9r−0.9—−15.6% | −1.2−6716%−33.5% | 0.0+628%0.7% | 0.0—0.2% | — | |
| Net income including minority interests | — | — | — | — | — | −24—−673% | −45—−1889% | −56—−5616% | −36—−4440% | |
| Minority interests' share of net income | — | — | — | — | — | — | — | 0.1—5.5% | −0.2—−29.1% | |
| Net income attributable to shareholders | −14—−43.6% | −12—−47.2% | −19—−117% | −22—−258% | −17r−17—−316% | −24—−673% | −45—−1889% | −56—−5622% | −36—−4411% | |
| Earnings per share, basic | -1.65—— | -1.59—— | -3.42—— | -4.69—— | -4.36r-0.29—— | -0.60—— | -1.54—— | -1.19—— | — | |
| Earnings per share, diluted | -1.65—— | -1.59—— | -3.42—— | -4.69—— | -4.36r-0.29—— | -0.60—— | -1.54—— | -1.19—— | — | |
| Shares, weighted average (basic) | 0.0+13.4%— | 0.0r7.5−99.9%— | 5.5r0.0+116521%— | 0.0+19.9%— | 0.0—— | — | — | — | — | |
| Shares, weighted average (diluted) | 0.0+13.4%— | 0.0r7.5−99.9%— | 5.5r0.0+116521%— | 0.0+19.9%— | 0.0r59−100.0%— | 39+32.7%— | 29+0.4%— | 29—— | — | |
| Balance sheet | ||||||||||
| Cash and cash equivalents | 7.0+90.1%37.7% | 3.7r3.5−64.2%18.1% | 10−41.7%64.2% | 18−48.9%71.5% | 35r35+718%81.0% | 4.2−68.7%13.5% | 14+78.5%38.2% | 7.6−42.5%10.3% | 13—33.7% | |
| Short-term investments | 4.6−46.3%24.5% | 8.5—41.6% | — | — | — | 18+75.2%58.3% | 10−82.8%29.6% | 61+155%82.9% | 24—61.0% | |
| Receivables | 1.0−24.9%5.5% | 1.4+90.7%6.7% | 0.7+78.8%4.5% | 0.4−8.4%1.6% | 0.4r0.4+61.9%1.0% | 0.3−45.5%0.9% | 0.5+85.4%1.4% | 0.3+159%0.4% | 0.1—0.3% | |
| Inventory | 1.6−2.7%8.7% | 1.7−22.4%8.2% | 2.2+9.0%13.4% | 2.0+45.6%8.0% | 1.4r1.4+55.3%3.2% | 0.9−1.6%2.8% | 0.9−54.3%2.5% | 1.9+495%2.7% | 0.3—0.8% | |
| Other current assets | 1.4+34.6%7.5% | 1.0+24.2%5.1% | 0.8+1.0%5.2% | 0.8−21.4%3.3% | 1.1r1.1−18.3%2.5% | 1.3+18.5%4.1% | 1.1−43.3%3.1% | 1.9+236%2.6% | 0.6—1.5% | |
| Current assets | 16−3.9%83.9% | 16+14.0%79.6% | 14−32.5%88.8% | 21−43.6%85.5% | 38r38+49.8%87.6% | 25−5.5%79.5% | 27−63.5%74.8% | 73+86.2%98.9% | 39—99.5% | |
| Property, plant and equipment | 0.4+142%2.0% | 0.2−22.5%0.8% | 0.2+308%1.3% | 0.1−66.0%0.2% | 0.1r0.1−39.8%0.3% | 0.2−29.3%0.8% | 0.3−9.4%1.0% | 0.4+126%0.5% | 0.2—0.4% | |
| Right-of-use (leased) assets | 2.6−31.4%13.7% | 3.7+645%18.3% | 0.5−11.2%3.1% | 0.6−7.8%2.3% | 0.6r0.6+18.5%1.4% | 0.5−63.8%1.6% | 1.4—4.0% | — | — | |
| Total assets | 19−8.8%100% | 20+27.1%100% | 16−35.0%100% | 25−42.2%100% | 43r43+35.9%100% | 32−11.1%100% | 35−51.8%100% | 74+87.4%100% | 39—100% | |
| Accounts payable | 2.7+48.4%14.5% | 1.8−15.5%8.9% | 2.2+1.6%13.4% | 2.1+127%8.6% | 0.9r1.5−54.9%2.2% | 2.1−60.1%6.6% | 5.2+93.0%14.7% | 2.7+221%3.7% | 0.8—2.1% | |
| Debt due within a year | — | — | — | — | — | 0.3—1.0% | — | — | — | |
| Current liabilities | 11+24.0%60.8% | 9.2+12.7%44.7% | 8.1+15.3%50.4% | 7.0+28.4%28.5% | 5.5r5.5−6.9%12.8% | 5.9−35.6%18.7% | 9.1+29.3%25.8% | 7.1+15.6%9.6% | 6.1—15.6% | |
| Long-term debt | 6.6—35.4% | — | — | — | — | 1.1—3.5% | — | — | — | |
| Lease liabilities (non-current) | 2.4−35.9%13.0% | 3.8+603%18.4% | 0.5−14.1%3.3% | 0.6−10.7%2.5% | 0.7r0.7−20.9%1.6% | 0.9−37.6%2.8% | 1.4—4.0% | — | — | |
| Total liabilities | 20+57.6%109% | 13+49.3%63.1% | 8.7+12.9%53.8% | 7.7+24.0%31.0% | 6.2r6.2−21.4%14.4% | 7.9−25.5%25.0% | 11+44.4%29.8% | 7.3+13.9%10.0% | 6.4—16.4% | |
| Retained earnings | −191—−1023% | −177—−865% | −165—−1026% | −146—−591% | −124r−124—−290% | −107—−339% | −83—−235% | −38—−52.1% | −153—−390% | |
| Shareholders' equity | −1.7−123%−9.2% | 7.5+1.4%36.9% | 7.4−56.4%46.2% | 17−53.4%69.0% | 37r37+59.3%85.6% | 23−5.2%73.0% | 24−63.0%68.4% | 66—89.2% | −90—−230% | |
| Minority interests | — | — | — | — | — | 0.60.0%2.0% | 0.60.0%1.8% | 0.6+5.2%0.9% | 0.6—1.5% | |
| Total equity | — | — | — | 17−53.3%69.0% | 37r37+54.7%85.4% | 24r24−5.0%75.0% | 25−62.4%70.2% | 66—90.0% | −89—−228% | |
| Total liabilities and equity | 19−8.8%100% | 20+27.1%100% | 16−35.0%100% | 25−42.2%100% | 43r43+35.9%100% | 32−11.1%100% | 35−51.8%100% | 74+87.4%100% | 39—100% | |
| Shares outstanding | 8.0+20.4%— | 6.7+10.8%— | 6.0+26.5%— | 4.7+0.7%— | 4.7r71−89.7%— | 46+52.7%— | 30+1.3%— | 29—— | — | |
| Cash-flow statement | ||||||||||
| Depreciation and amortization | 0.5−34.1%1.6% | 0.8−21.0%3.0% | 1.0+75.5%6.0% | 0.5+43.5%6.4% | 0.4r0.4−4.3%7.0% | 0.4+60.0%11.4% | 0.2+274%10.4% | 0.1+106%6.7% | 0.0—4.0% | |
| Share-based compensation | 1.9+3.2%6.0% | 1.9+10.1%7.4% | 1.7−36.7%10.6% | 2.7−18.8%31.2% | 3.3r3.3+1.1%60.6% | 3.3−16.2%93.4% | 3.9−48.7%163% | 7.6+1544%765% | 0.5—57.0% | |
| Cash from operating activities | −8.2—−25.6% | −6.9—−27.6% | −15—−91.5% | −17—−194% | −14r−14—−250% | −20r−20—−574% | −45—−1885% | −47—−4744% | −25—−3121% | |
| Capital expenditure | −0.1—−0.2% | — | −0.2—−1.3% | — | — | — | −0.1—−2.9% | −0.3—−28.1% | −0.2—−18.8% | |
| Cash from investing activities | 3.9—12.1% | −8.5—−33.8% | −0.2—−1.3% | — | 18r18—334% | −8.0−116%−228% | 51—2132% | −37—−3709% | −24—−2972% | |
| Debt issued | 7.5—23.4% | — | — | — | — | — | — | — | — | |
| Shares issued | — | — | 8.1—50.8% | — | — | — | — | 78—7889% | — | |
| Cash from financing activities | 7.6−9.6%23.8% | 8.4+12.7%33.5% | 7.5—46.7% | — | 26r26+35.9%471% | 19r19+11651%541% | 0.2−99.8%6.7% | 78+25.4%7889% | 62—7701% | |
| Exchange-rate effect on cash | 0.0−87.8%0.1% | 0.1—0.6% | — | — | — | — | — | −0.0—−2.0% | −0.2—−28.5% | |
| Change in cash | — | −6.9—−27.3% | −7.4—−46.0% | −17−155%−195% | 30r30—559% | −9.3−256%−267% | 6.0—249% | −5.6−144%−566% | 13—1578% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 38+27.3%100% | 9.7+11.5%100% | 9.5+28.0%100% | 9.6+42.6%100% | 9.2*+31.2%100% | 8.7+32.6%100% | 7.4+20.2%100% | 6.7+23.4%100% | 7.0*+35.7%100% | 6.6—100% | 6.1—100% | 5.4—100% | 5.2*—100% | |
| Cost of revenue | 4.7+12.4%12.3% | 1.1−8.4%11.5% | 1.3+35.6%13.5% | 1.2+20.4%12.7% | 1.1*+7.9%11.6% | 1.2+14.5%14.0% | 0.9+12.1%12.7% | 1.0+14.1%15.1% | 1.0*−9.6%14.1% | 1.1—16.2% | 0.8—13.7% | 0.9—16.3% | 1.1*—21.2% | |
| Gross profit | 33+29.7%87.7% | 8.6+14.8%88.5% | 8.2+26.9%86.5% | 8.4+46.6%87.3% | 8.2*+35.0%88.4% | 7.5+36.1%86.0% | 6.4+21.5%87.3% | 5.7+25.3%84.9% | 6.1*+47.9%85.9% | 5.5—83.8% | 5.3—86.3% | 4.6—83.7% | 4.1*—78.8% | |
| Research and development | — | — | — | — | — | 0.7+27.1%7.6% | 0.5−19.5%6.9% | 0.6+60.9%9.6% | 0.8*−27.3%11.4% | 0.5—7.9% | 0.6—10.3% | 0.4—7.3% | 1.1*—21.3% | |
| Selling, general and administrative | 43+18.2%113% | 9.7+0.1%100% | 10+7.4%107% | 13+45.6%135% | 10*+22.5%110% | 9.7+27.2%112% | 9.4+30.0%128% | 8.9+11.0%132% | 8.3*+19.8%118% | 7.6—116% | 7.3—118% | 8.0—147% | 6.9*—134% | |
| Operating expenses | 46+17.8%121% | 10−2.2%105% | 11+10.1%116% | 14+43.6%143% | 11*+21.8%120% | 10+27.2%119% | 9.9+26.1%135% | 9.5+13.4%142% | 9.1*+13.3%129% | 8.1—124% | 7.9—129% | 8.4—154% | 8.0*—155% | |
| Operating income | −13—−33.1% | −1.6—−16.1% | −2.8—−29.3% | −5.3—−55.5% | −2.9*—−31.8% | −2.9—−33.2% | −3.5—−47.5% | −3.8—−56.9% | −3.1*—−43.6% | −2.7—−40.4% | −2.6—−42.2% | −3.8—−70.7% | −4.0*—−76.2% | |
| Interest expense and finance costs | 0.0−28.0%0.0% | 0.0+12.1%0.0% | 0.0−26.7%0.0% | 0.0−20.0%0.0% | 0.0*−61.1%0.0% | 0.0−34.0%0.0% | 0.0+4.7%0.1% | 0.0+19.0%0.1% | 0.0*—0.1% | 0.0—0.1% | 0.0—0.1% | 0.0—0.1% | — | |
| Other non-operating income (expense) | −0.5—−1.4% | 0.1—0.9% | −0.3—−3.0% | −0.3—−2.9% | −0.0*—−0.5% | −0.5−438%−6.0% | −0.2—−2.2% | −0.1−137%−1.2% | −0.1*—−1.8% | 0.2—2.3% | −0.1—−1.0% | 0.2—4.1% | −0.0*—−0.9% | |
| Income before tax | −13—−34.5% | −1.5—−15.1% | −3.1—−32.4% | −5.6—−58.3% | −3.0*—−32.3% | −3.4—−39.2% | −3.7—−49.7% | −3.9—−58.1% | −3.2*—−45.4% | −2.5—−38.1% | −2.7—−43.2% | −3.6—−66.7% | −4.0*—−77.2% | |
| Income tax | −0.4—−1.0% | −0.1—−1.3% | 0*—0.0% | −0.3—−3.3% | 0.1*+75.9%0.6% | 0*—0.0% | 0*—0.0% | −0.0—−0.7% | 0.0*+16.0%0.4% | 0*—0.0% | 0*—0.0% | −0.1—−2.2% | 0.0*—0.5% | |
| Net income attributable to shareholders | −13—−33.5% | −1.3—−13.8% | −3.1—−32.4% | −5.3—−55.0% | −3.0*—−32.8% | −3.4—−39.2% | −3.7—−49.7% | −3.9—−57.4% | −3.2*—−45.8% | −2.5—−38.1% | −2.7—−43.2% | −3.5—−64.4% | −4.0*—−77.7% | |
| Earnings per share, basic | — | -0.13—— | -0.33—— | -0.59—— | — | -0.40—— | -0.44—— | -0.47—— | — | -0.31—— | -0.38—— | -0.53—— | — | |
| Earnings per share, diluted | — | -0.13—— | -0.33—— | -0.59—— | — | -0.40—— | -0.44—— | -0.47—— | — | -0.31—— | -0.38—— | -0.53—— | — | |
| Shares, weighted average (basic) | 10.0+17.9%— | 10.0+17.9%— | 0.0+13.1%— | 0.0+8.0%— | — | 8.4r0.0+104249%— | 0.0+18.0%— | 0.0+25.3%— | — | 0.0r8.1—— | 0.0r7.0—— | 0.0r6.6—— | — | |
| Shares, weighted average (diluted) | 10.0+17.9%— | 10.0+17.9%— | 0.0+13.1%— | 0.0+8.0%— | — | 8.4r0.0+104249%— | 0.0+18.0%— | 0.0+25.3%— | — | 0.0r8.1—— | 0.0r7.0—— | 0.0r6.6—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 6.3—36.5% | 6.3−19.7%36.5% | 8.5+152%49.8% | 4.9+28.5%31.3% | 7.0+90.1%37.7% | 7.9+59.4%36.7% | 3.4−67.3%23.2% | 3.8−51.9%23.5% | 3.7r3.5−64.2%18.1% | 4.9—23.4% | 10—46.1% | 7.8—56.5% | 10—64.2% | |
| Short-term investments | 1.2—6.9% | 1.2−76.5%6.9% | 1.5−59.1%9.0% | 4.0−0.1%25.7% | 4.6−46.3%24.5% | 5.1−36.5%23.8% | 3.8−4.0%25.9% | 4.0—24.8% | 8.5—41.6% | 8.0—38.1% | 3.9—17.6% | — | — | |
| Receivables | 1.6—9.4% | 1.6+9.5%9.4% | 0.9+11.8%5.3% | 0.9−40.2%5.6% | 1.0−24.9%5.5% | 1.5+168%6.9% | 0.8+51.1%5.6% | 1.5+207%9.1% | 1.4+90.7%6.7% | 0.6—2.6% | 0.5—2.4% | 0.5—3.4% | 0.7—4.5% | |
| Inventory | 4.0—22.9% | 4.0+227%22.9% | 2.4+69.4%14.2% | 2.0+14.1%12.8% | 1.6−2.7%8.7% | 1.2−38.1%5.7% | 1.4−44.7%9.8% | 1.7−30.9%10.8% | 1.7−22.4%8.2% | 2.0—9.3% | 2.6—11.5% | 2.5—18.0% | 2.2—13.4% | |
| Other current assets | 1.4—7.9% | 1.4−6.3%7.9% | 0.8−18.4%4.4% | 0.8+9.7%5.5% | 1.4+34.6%7.5% | 1.5+35.8%6.8% | 0.9+156%6.3% | 0.8+22.6%4.8% | 1.0+24.2%5.1% | 1.1—5.1% | 0.4—1.6% | 0.6—4.5% | 0.8—5.2% | |
| Current assets | 14—83.7% | 14−16.7%83.7% | 14+33.8%82.8% | 13+4.6%80.9% | 16−3.9%83.9% | 17+3.4%81.0% | 11−41.2%72.5% | 12+2.2%74.6% | 16+14.0%79.6% | 17—79.7% | 18—80.3% | 12—84.3% | 14—88.8% | |
| Property, plant and equipment | 0.4—2.1% | 0.4+91.2%2.1% | 0.4+90.4%2.2% | 0.4+98.9%2.4% | 0.4+142%2.0% | 0.2+14.1%0.9% | 0.2+8.8%1.4% | 0.2−4.7%1.1% | 0.2−22.5%0.8% | 0.2—0.8% | 0.2—0.8% | 0.2—1.4% | 0.2—1.3% | |
| Right-of-use (leased) assets | 2.4—13.8% | 2.4−34.2%13.8% | 2.5−31.4%14.7% | 2.5−31.4%16.4% | 2.6−31.4%13.7% | 3.6−2.8%16.9% | 3.7−3.0%25.2% | 3.7+140%23.1% | 3.7+645%18.3% | 3.7—17.7% | 3.8—16.9% | 1.5—11.1% | 0.5—3.1% | |
| Total assets | 17—100% | 17−19.4%100% | 17+17.2%100% | 15−3.5%100% | 19−8.8%100% | 21+1.7%100% | 15−34.9%100% | 16+15.5%100% | 20+27.1%100% | 21—100% | 22—100% | 14—100% | 16—100% | |
| Accounts payable | 3.4—20.0% | 3.4+12.2%20.0% | 2.2−15.0%12.8% | 2.2+23.2%14.0% | 2.7+48.4%14.5% | 3.1+147%14.3% | 2.6+76.3%17.6% | 1.8−24.0%11.0% | 1.8−15.5%8.9% | 1.2—5.9% | 1.5—6.5% | 2.3—16.7% | 2.2—13.4% | |
| Current liabilities | 11—62.5% | 11−11.2%62.5% | 12+21.4%68.4% | 12+56.7%79.5% | 11+24.0%60.8% | 12+53.5%56.7% | 9.6+32.6%66.1% | 7.9+0.4%49.0% | 9.2+12.7%44.7% | 7.9—37.6% | 7.3—32.4% | 7.8—56.3% | 8.1—50.4% | |
| Long-term debt | 6.6—38.1% | 6.6+0.9%38.1% | 5.8—33.8% | 6.4—41.6% | 6.6—35.4% | 6.5—30.5% | — | — | — | — | — | — | — | |
| Lease liabilities (non-current) | 2.4—13.9% | 2.4−37.0%13.9% | 2.4−37.0%14.1% | 2.4−36.6%15.6% | 2.4−35.9%13.0% | 3.8+3.8%17.8% | 3.8+5.4%26.3% | 3.8+144%23.8% | 3.8+603%18.4% | 3.7—17.5% | 3.6—16.2% | 1.6—11.3% | 0.5—3.3% | |
| Total liabilities | 20—115% | 20−12.1%115% | 20+47.7%116% | 21+81.3%137% | 20+57.6%109% | 22+94.0%105% | 13+23.6%92.4% | 12+24.3%72.8% | 13+49.3%63.1% | 12—55.1% | 11—48.7% | 9.4—67.6% | 8.7—53.8% | |
| Retained earnings | −201—−1163% | −201—−1163% | −199—−1168% | −196—−1268% | −191—−1023% | −188—−878% | −185—−1268% | −181—−1128% | −177—−865% | −174—−826% | −171—−767% | −169—−1215% | −165—−1026% | |
| Shareholders' equity | −2.5—−14.5% | −2.5—−14.5% | −2.8−351%−16.4% | −5.7−230%−36.7% | −1.7−123%−9.2% | −1.1−111%−5.0% | 1.1−90.3%7.6% | 4.4−2.9%27.2% | 7.5+1.4%36.9% | 9.5—44.9% | 11—51.3% | 4.5—32.4% | 7.4—46.2% | |
| Total liabilities and equity | 17—100% | 17−19.4%100% | 17+17.2%100% | 15−3.5%100% | 19−8.8%100% | 21+1.7%100% | 15−34.9%100% | 16+15.5%100% | 20+27.1%100% | 21—100% | 22—100% | 14—100% | 16—100% | |
| Shares outstanding | 9.2—— | 9.2+20.2%— | 9.0+20.6%— | 8.1+9.5%— | 8.0+20.4%— | 7.6+17.3%— | 7.5+15.8%— | 7.4+23.5%— | 6.7+10.8%— | 6.5—— | 6.4—— | 6.0—— | 6.0—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.1−74.6%0.4% | 0.0*−92.4%0.1% | 0.0*−95.0%0.1% | 0.0−86.5%0.2% | 0.1*−36.3%1.2% | 0.1*−36.2%1.4% | 0.1*−39.8%1.6% | 0.2−24.8%2.3% | 0.2*−26.0%2.4% | 0.2*—2.8% | 0.2*—3.3% | 0.2—3.8% | 0.2*—4.4% | |
| Share-based compensation | 2.9+45.8%7.6% | 0.6*+48.7%6.4% | 0.8+49.5%8.0% | 1.0+91.9%10.8% | 0.5*−8.6%5.1% | 0.4+3.8%4.8% | 0.5+7.0%6.8% | 0.5+11.6%8.0% | 0.5*+28.5%7.3% | 0.4—6.1% | 0.5—7.7% | 0.5—8.9% | 0.4*—7.7% | |
| Cash from operating activities | −11—−28.7% | −2.8*—−29.2% | −3.5*—−37.2% | −3.0—−31.4% | −1.5*—−16.7% | −1.7*—−19.2% | −0.6*—−8.4% | −4.4—−64.8% | −1.3*—−17.8% | −1.4*—−20.8% | −1.8*—−28.9% | −2.6—−47.0% | −3.1*—−60.2% | |
| Capital expenditure | −0.0—−0.0% | 0*—0.0% | −0.0*—−0.0% | −0.0—−0.0% | 0*—0.0% | −0.0*—−0.0% | −0.0*—−0.3% | −0.0—−0.6% | — | — | — | — | −0.0*—−0.8% | |
| Cash from investing activities | 3.9+36.2%10.3% | 0.3*—3.6% | 2.4*+1214%25.7% | 0.6−86.7%6.2% | 0.5*—5.6% | −1.3*—−15.3% | 0.2*—2.5% | 4.5—67.0% | −0.5*—−7.1% | −4.1*—−62.4% | — | — | −0.0*—−0.8% | |
| Debt issued | — | — | — | — | 0.1r0*—1.0% | — | — | — | — | — | — | — | — | |
| Shares issued | — | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | |
| Cash from financing activities | 5.2−35.0%13.8% | 0.3*−96.2%3.0% | 4.7*+158033%50.2% | 0.2+27.8%2.4% | −0.0*−111%−0.4% | 7.5*—86.1% | 0.0*—0.0% | 0.2—2.7% | 0.4*—5.3% | −0.1*—−0.8% | — | — | 0*—0.0% | |
| Exchange-rate effect on cash | −0.0—−0.1% | −0.0*—−0.0% | −0.0*−123%−0.1% | −0.0−200%−0.0% | −0.0*—−0.1% | −0.0*−104%−0.1% | 0.0*−6.1%0.4% | 0.0−97.4%0.0% | −0.1*—−1.3% | 0.1*—2.0% | 0.0*—0.5% | 0.1—1.4% | — | |
| Change in cash | — | — | — | — | — | — | — | — | −1.5*—−21.0% | −5.4*—−82.0% | 2.5*—40.0% | −2.5—−45.6% | −3.1*—−60.3% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What electroCore, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Product(total)$32 M100%+27%
- License$0 M0.2%+0.0%
Business segments
- Bioelectronic Innovations$32 M100%+27%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where electroCore, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 2 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office1 subsidiary | — |
| 🇩🇪 Germany | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at electroCore, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Daniel Goldberger | $1.6 M | $226 K | $707 K | $116 |
| 2024Daniel Goldberger | $1.6 M | $2.7 M | $601 K | $420 |
| 2023Daniel Goldberger | $1.3 M | $1.3 M | $679 K | $154 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at electroCore, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Auditor changedFiling
Auditor changed 1 · Acquisition or sale completed 1 · Directors and officers 5 · Material agreement 3 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 12
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officersBylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Acquisition or sale completed | 8-K | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share sale | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 4, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2025 | $2 M | Private placement after listing | Under $2 million | 3 | equity | SEC |
| Jun 2024 | $8 M | Private placement after listing | $2 to $10 million | 13 | equity, options | SEC |
| May 2020 | $2 M | Private placement after listing | Under $2 million | 1 | equity | SEC |
| Apr 2020 | $2 M | Private placement after listing | Under $2 million | 3 | equity | SEC |
| Aug 2017 | $71 M | No. 1 | $50 to $250 million | 94 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How electroCore, Inc. compares in Medical Instruments
- Market cap$75 M · higher than 12% of 116
- Revenue$32 M · higher than 10% of 120
- Net margin-33.5% · higher than 9% of 114
- Revenue growth27.2% · higher than 92% of 49
- Price / sales2.0× · lower than 73% of 85
- FCF yield-11.0% · higher than 16% of 39
Peer comparison · Medical Instruments
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| electroCore, Inc.🇺🇸 | $75 M | — | -33.5% | +27.2% |
| Intuitive Surgical, Inc.🇺🇸 | $155.6 B | 52.6× | 25.5% | +20.5% |
| EssilorLuxottica S.A.🇫🇷 | $88.0 B | 32.1× | 8.1% | +4.5% |
| HOYA Corporation🇯🇵 | $56.2 B | 32.8× | 25.4% | — |
| Becton, Dickinson and Company🇺🇸 | $54.0 B | 57.4× | 4.2% | +8.2% |
| Alcon Inc.🇨🇭 | $37.1 B | 37.9× | 9.4% | +4.9% |
| ResMed Inc.🇺🇸 | $35.3 B | 22.1× | 27.8% | +9.8% |
| West Pharmaceutical Services, Inc.🇺🇸 | $27.1 B | 42.4× | 18.8% | +6.3% |
| Terumo Corporation🇯🇵 | $24.9 B | 27.0× | 12.0% | — |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Microbot Medical Inc.$75 M
- Nyxoah SA$71 M
- Nang Kuang Pharmaceutical Co., Ltd.$90 M
- Icares Medicus, Inc.$92 M
- Daxor Corporation$61 M
- Stereotaxis, Inc.$92 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of February 1, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at electroCore, Inc.? Verify and update this profile — free
Show electroCore, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.